FDA UDI
In Commercial Distribution
🇺🇸 United States
CytoCell
DI: 05055844934894
·
Model: CDA-LPH013
·
CYTOCELL LIMITED
Product Codes
1
GMDN Terms
2
Identifiers
1
Pkg Device Count
1
Basic Information
- Brand Name
- CytoCell
- Primary DI
- 05055844934894
- Version / Model
- CDA-LPH013
- Company Name
- CYTOCELL LIMITED
- Labeler DUNS
- 232477914
- Distribution Status
- In Commercial Distribution
- Device Count in Pkg
- 1
- Record Status
- Published
- Publish Date
- 2025-09-22
- Public Version
- 1
- Public Version Date
- 2025-09-30
- Public Version Status
- New
- Public Device Record Key
- a0e9a291-4725-45ea-a5f0-a3eb1fd1b8d5
Device Description
KMT2A Breakapart FISH Probe Kit PDx
Device Characteristics
- Single Use
- No
- Prescription Use (Rx)
- Yes
- Over the Counter (OTC)
- No
- Kit
- Yes
- Combination Product
- No
- HCT/P
- No
- Contains NRL
- No
- Not Made with NRL
- No
- MRI Safety
- Labeling does not contain MRI Safety Information
- Direct Marking Exempt
- No
- PM Exempt
- No
- Has Serial Number
- No
- Has Lot/Batch Number
- Yes
- Has Manufacturing Date
- No
- Has Expiration Date
- Yes
- Has Donation ID
- No
Sterilization
- Is Sterile
- No
- Sterilization Prior Use
- No
Product Codes
| Code | Name | Medical Specialty | Regulation # | Device Class |
|---|---|---|---|---|
| SFS | Revumenib Eligibility Detection System | Hematology | 864.1885 | 2 |
GMDN Terms
| Code | Name | Definition | Implantable | Status |
|---|---|---|---|---|
| 60079 | Acute myeloid leukaemia (AML) genetic mutation IVD, probe | A defined piece of single-stranded nucleic acid which is used to identify specific complementary-sequence nucleic acid molecules in an assay intended to be used to evaluate a clinical specimen to diagnose, monitor or predict acute myeloid leukaemia (AML) based on changes at the gene or chromosomal level which may include FLT3 gene mutations, NPM1 gene mutations, t(8;21), inv(16) and/or t(15;17). | No | Active |
| 62955 | B-cell malignancy IVD, probe | A defined piece of single-stranded nucleic acid which is used to identify specific complementary-sequence nucleic acid molecules in an assay intended to be used to evaluate a clinical specimen to detect and/or monitor B-cell malignancies. Genetic changes associated with B-cell malignancies are typically associated with chromosomal translocations and gene rearrangements involving various genes/loci such as cyclin D1 (CCND1), immunoglobulin heavy or light chain genes (e.g., IGH, IGK, IGL), myc, and B-cell lymphoma genes (e.g., BCL1, BCL2). | No | Active |
Identifiers
| Type | ID | Issuing Agency | Package Type | Qty per Pkg | Pkg Status | Pkg Discontinue Date |
|---|---|---|---|---|---|---|
| Primary | 05055844934894 | GS1 |
Customer Contacts
- Phone
- 914 467 5285
- [email protected]
Premarket Submissions
| Submission Number | Supplement Number |
|---|---|
| DEN240067 | 000 |
Storage Conditions
- Type
- Storage Environment Temperature
- Temperature Range
- -25 – -15 Degrees Celsius
- Type
- Special Storage Condition, Specify
- Special Conditions
- Store the probe vial in the dark. Ensure that exposure of the probe to laboratory lights is limited at all times